Recent Company News

• 07:08 AM ET Apr 16, 2026
  

  Biotest changes its legal form to Biotest GmbH & Co. KGaA (€32.00, 0.00)

• 06:04 AM ET Dec 19, 2025
  

  Biotest announces US FDA approval of Grifols' Fesilty (fibrinogen, human-chmt) (€31.40, -0.20)

• 04:11 AM ET Nov 13, 2025
  

  Biotest obtains approval for new human fibrinogen Prufibry in Germany (€30.00, 0.00)

• 09:25 AM ET Nov 07, 2025
  

  Biotest to convene again an extraordinary general meeting for 17-Dec-25 at the request of Grifols S.A. (€30.00, 0.00)

• 11:39 AM ET Oct 09, 2025
  

  Biotest's Yimmugo launches in the U.S. (€28.20, 0.00)

• 11:33 AM ET Oct 09, 2025
  

  Biotest's launches Yimmugo to treat primary immunodeficiencies, in the United States. (€28.20, 0.00)

• 09:06 AM ET Sep 19, 2025
  

  Biotest convenes EGM on 28-Oct at request of Grifols S.A. (€30.00, 0.00)

• 01:14 PM ET Jun 11, 2025
  

  Grifols successfully completes Biotest delisting (€10.47, 0.00)

• 10:53 AM ET Jun 03, 2025
  

  Biotest AG announces delisting of Biotest shares from the Frankfurt Stock Exchange with effect from 6-Jun-25 (€29.80, -0.20)

• 11:04 AM ET May 28, 2025
  

  Biotest today decided to replace its CEO, Mr Janssen, with immediate effect (€42.60, -0.20)